peptide garden
Regulatory tracker

Peptide Legal Status Tracker

A live source-check view of which tracked peptides are FDA-approved, Category 1, Category 2, recommended by the advisory committee, investigational, or not currently compoundable.

Statuses overlap. FDA approval, Category 1 compounding posture, an advisory-committee recommendation, and an actual list change are four different legal concepts. This page is educational context, not medical or legal advice.

The one thing to know right now

On July 23-24, 2026 the FDA advisory committee recommended six of seven peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for the 503A Bulks List, over its own review team's objection. That is a recommendation, not a rule. FDA has taken no action since, so none of those six is legal to compound today. The detail is on our July 2026 PCAC hub.

Source check

Last checked October 1, 2026

Anchored to FDA bulk-substance pages, safety-risk pages, the July 2026 PCAC meeting materials, the Federal Register, FDA import alerts, and Drugs@FDA records.

Category 1

FDA's current interim 503A posture for nominated bulk drug substances that may be used in compounding if all legal conditions are met. This is not FDA drug approval.

3

Category 2

FDA has identified significant safety risks for these substances and has placed them in category 2 of its interim compounding policies. In April 2026 FDA split this page in two: a shrinking active category 2 table, and a separate 'nominated but withdrawn' table for substances whose nominations the nominators pulled. Both mean the same thing in practice — not currently compoundable.

5

PCAC review

The Pharmacy Compounding Advisory Committee has reviewed, or is scheduled to review, the substance for possible 503A bulk-list inclusion. Recommendations are advisory, not final FDA approval.

12

PCAC recommended

The advisory committee voted to recommend adding the substance to the 503A Bulks List at its July 23-24, 2026 meeting. A recommendation is advisory only. FDA must still complete notice-and-comment rulemaking, and it had taken no action as of August 22, 2026, so these substances are not legal to compound today.

6

FDA-approved

At least one FDA-approved drug product exists for the active ingredient. This does not authorize non-approved uses or unrestricted copy compounding.

7

Investigational

The peptide is in clinical development or limited research use and is not FDA-approved for routine prescribing.

3

Not compoundable

No current federal bulk-substance path is identified for routine compounding, or FDA has explicitly stated the substance cannot be used in compounding.

18
Status lanes

Current categories at a glance

These lanes are tag-based, so a peptide can appear in more than one lane. For example, a PCAC-reviewed peptide may also be not currently compoundable.

Category 1

FDA's current interim 503A posture for nominated bulk drug substances that may be used in compounding if all legal conditions are met. This is not FDA drug approval.

3 tracked
GHK-Cu

Glycyl-L-histidyl-L-lysine copper

Category 1PCAC review

Category 1 in FDA's 503A materials for non-injectable routes. Injectable GHK-Cu is not on that footing and is not authorized for compounding. Its position moved in April 2026: injectable GHK-Cu was one of the twelve peptides shifted off FDA's active category 2 table into the new 'nominated but withdrawn' table. FDA still publishes its safety-risk finding, and the substance is no closer to being compoundable — a withdrawn nomination is a nomination that will not be decided, not a clearance. Law-firm reporting from the July 2026 PCAC meeting says FDA signalled a further PCAC consultation on GHK-Cu and four other peptides; FDA has published no meeting notice, docket, or date for it, so we treat the timing as unconfirmed.

A second peptide PCAC meeting including GHK-Cu is reported but unscheduled. Watching the FDA advisory committee calendar and the Federal Register.

NAD+

Nicotinamide adenine dinucleotide

Category 1Not a peptide

Category 1 in the current FDA 503A list. It is a coenzyme, not a peptide, and Category 1 is not FDA drug approval.

Vasoactive intestinal peptide

VIP

Category 1

Category 1 in the current FDA 503A list if all compounding conditions are met.

Category 2

FDA has identified significant safety risks for these substances and has placed them in category 2 of its interim compounding policies. In April 2026 FDA split this page in two: a shrinking active category 2 table, and a separate 'nominated but withdrawn' table for substances whose nominations the nominators pulled. Both mean the same thing in practice — not currently compoundable.

5 tracked
Kisspeptin-10

Kisspeptin fragment

Category 2InvestigationalNot compoundable

Category 2 under 503A, added September 29, 2023, and still there. After FDA's April 2026 restructure, kisspeptin-10, ipamorelin acetate, GHRP-2 (injectable/nasal routes), and GHRP-6 are the four peptides left in the active category 2 table — everything else moved to the 'nominated but withdrawn' table. Treat as not currently compoundable.

Ipamorelin acetate

Growth hormone secretagogue

Category 2PCAC reviewNot compoundable

Category 2 for 503B outsourcing facilities, added September 29, 2023, and still there — one of four peptides remaining in FDA's active category 2 table. Its separate 503A nomination was withdrawn, so ipamorelin acetate is the one substance that appears in both of FDA's tables at once. Not a Category 1 503A bulk substance.

GHRP-2

Growth hormone releasing peptide-2

Category 2Not compoundable

Category 2 for injectable and nasal routes in FDA's safety-risk materials. Treat as not currently compoundable.

GHRP-6

Growth hormone releasing peptide-6

Category 2Not compoundable

Category 2 in FDA's safety-risk materials. Treat as not currently compoundable.

Ibutamoren

MK-677

Category 2Not compoundableNon-peptide secretagogue

Category 2 in the current FDA 503A list. Included because it is frequently grouped with growth hormone peptides in consumer searches.

PCAC review

The Pharmacy Compounding Advisory Committee has reviewed, or is scheduled to review, the substance for possible 503A bulk-list inclusion. Recommendations are advisory, not final FDA approval.

12 tracked
GHK-Cu

Glycyl-L-histidyl-L-lysine copper

Category 1PCAC review

Category 1 in FDA's 503A materials for non-injectable routes. Injectable GHK-Cu is not on that footing and is not authorized for compounding. Its position moved in April 2026: injectable GHK-Cu was one of the twelve peptides shifted off FDA's active category 2 table into the new 'nominated but withdrawn' table. FDA still publishes its safety-risk finding, and the substance is no closer to being compoundable — a withdrawn nomination is a nomination that will not be decided, not a clearance. Law-firm reporting from the July 2026 PCAC meeting says FDA signalled a further PCAC consultation on GHK-Cu and four other peptides; FDA has published no meeting notice, docket, or date for it, so we treat the timing as unconfirmed.

A second peptide PCAC meeting including GHK-Cu is reported but unscheduled. Watching the FDA advisory committee calendar and the Federal Register.

Ipamorelin acetate

Growth hormone secretagogue

Category 2PCAC reviewNot compoundable

Category 2 for 503B outsourcing facilities, added September 29, 2023, and still there — one of four peptides remaining in FDA's active category 2 table. Its separate 503A nomination was withdrawn, so ipamorelin acetate is the one substance that appears in both of FDA's tables at once. Not a Category 1 503A bulk substance.

BPC-157

BPC-157 free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend BPC-157, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported. FDA's own review team had recommended against all seven substances on the agenda, and its slides state that BPC-157 acetate 'is not well-characterized.' A recommendation is advisory. FDA has taken no action, so BPC-157 is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

KPV

KPV free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend KPV, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated use was wound healing and inflammatory conditions. A recommendation is advisory. FDA has taken no action, so KPV is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

TB-500

TB-500 free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend TB-500, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated use was wound healing. FDA opened the meeting with a talk on 'conflated bulks': one trade name can map to different sequences from different suppliers, which is exactly the TB-500 problem — the name is used for both full-length thymosin beta-4 and a short fragment. A recommendation is advisory. FDA has taken no action, so TB-500 is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

MOTS-c

MOTS-c free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend MOTS-c, free base and acetate salt, for the list — 7 yes, 5 no, 2 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated uses were obesity and osteoporosis. A recommendation is advisory. FDA has taken no action, so MOTS-c is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

Semax

Semax free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 24, 2026 the FDA advisory committee voted to recommend Semax, free base and acetate salt, for the list — 8 yes, 5 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated uses were cerebral ischemia, migraine, and trigeminal neuralgia. A recommendation is advisory. FDA has taken no action, so Semax is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

Emideltide / DSIP

Delta sleep-inducing peptide

PCAC hub
PCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. Emideltide was the only one of the seven substances the advisory committee voted against on July 24, 2026 — 6 yes, 7 no, 1 abstain as reported. FDA's evaluated uses were opioid withdrawal, chronic insomnia, and narcolepsy. Both the FDA review team and the committee landed against inclusion, so there is no pathway in progress.

No FDA action expected from this vote. Treat as not compoundable.

Epitalon

Epitalon free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 24, 2026 the FDA advisory committee voted to recommend Epitalon, free base and acetate salt, for the list — 7 yes, 4 no, 1 abstain as reported (some outlets reported 7-5-1; only 12 members were eligible to vote on this substance). FDA's evaluated use was insomnia. A recommendation is advisory. FDA has taken no action, so Epitalon is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

AOD-9604

hGH fragment 176-191

PCAC reviewNot compoundable

Not currently Category 1. FDA PCAC reviewed AOD-9604-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable.

CJC-1295

CJC-1295 related bulk drug substances

PCAC reviewNot compoundable

Not currently Category 1. FDA PCAC reviewed CJC-1295-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable.

Thymosin alpha-1

Thymosin alpha-1 free base and acetate

PCAC reviewNot compoundable

Not currently Category 1. FDA PCAC reviewed thymosin alpha-1-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable.

FDA-approved

At least one FDA-approved drug product exists for the active ingredient. This does not authorize non-approved uses or unrestricted copy compounding.

7 tracked
Semaglutide

GLP-1 receptor agonist

FDA-approved

FDA-approved products exist. Broad copy compounding is not a Category 1 peptide-bulk pathway, and FDA flags unapproved GLP-1 products and salt forms as safety risks. FDA's May 1, 2026 proposal to exclude semaglutide from the 503B outsourcing-facility bulks list on a 'no clinical need' finding closed for comment on or about July 30, 2026. As of August 22, 2026 FDA had issued no final determination and no follow-on Federal Register document, and no court challenge to the proposal had been filed. Separately, on July 28, 2026 FDA published revised draft product-specific guidances for generic semaglutide — a bioequivalence-recommendation update, not an approval, and not a change to compounding law.

Comment period on the proposed 503B bulks-list exclusion closed July 30, 2026 (docket FDA-2018-N-3240). Watching for a final FDA determination; none had issued as of August 22, 2026.

Tirzepatide

Dual GIP/GLP-1 receptor agonist

FDA-approved

FDA-approved products exist. Copy compounding is constrained by approved-drug and shortage rules, not Category 1 peptide-bulk status. FDA's May 1, 2026 proposal to exclude tirzepatide from the 503B outsourcing-facility bulks list on a 'no clinical need' finding closed for comment on or about July 30, 2026. As of August 22, 2026 FDA had issued no final determination and no follow-on Federal Register document. Separately, on July 28, 2026 FDA published revised draft product-specific guidances for generic tirzepatide — a bioequivalence-recommendation update, not an approval, and not a change to compounding law.

Comment period on the proposed 503B bulks-list exclusion closed July 30, 2026 (docket FDA-2018-N-3240). Watching for a final FDA determination; none had issued as of August 22, 2026.

Liraglutide

GLP-1 receptor agonist

FDA-approved

FDA-approved products exist. This is an approved-drug pathway, not a Category 1 peptide-bulk listing. FDA's May 1, 2026 proposal to exclude liraglutide from the 503B outsourcing-facility bulks list on a 'no clinical need' finding closed for comment on or about July 30, 2026, and FDA had issued no final determination as of August 22, 2026. Liraglutide is also covered by FDA's July 28, 2026 revised draft product-specific guidances for generic peptide products.

Comment period on the proposed 503B bulks-list exclusion closed July 30, 2026 (docket FDA-2018-N-3240). Watching for a final FDA determination; none had issued as of August 22, 2026.

Tesamorelin

GHRH analog

FDA-approved

FDA-approved product exists. Any compounding analysis starts from approved-drug rules rather than Category 1 bulk status.

PT-141 / Bremelanotide

Melanocortin receptor agonist

FDA-approved

FDA-approved product exists for a specific indication. That approval does not validate non-approved indications.

Oxytocin

Neuropeptide hormone

FDA-approved

FDA-approved drug products exist. This is not a consumer peptide-bulk compounding status.

Elamipretide

Mitochondria-targeted peptide

FDA-approved

FDA-approved product exists under an approved-drug pathway. It is not a Category 1 compounded bulk peptide.

Investigational

The peptide is in clinical development or limited research use and is not FDA-approved for routine prescribing.

3 tracked
Kisspeptin-10

Kisspeptin fragment

Category 2InvestigationalNot compoundable

Category 2 under 503A, added September 29, 2023, and still there. After FDA's April 2026 restructure, kisspeptin-10, ipamorelin acetate, GHRP-2 (injectable/nasal routes), and GHRP-6 are the four peptides left in the active category 2 table — everything else moved to the 'nominated but withdrawn' table. Treat as not currently compoundable.

Retatrutide

Triple GIP/GLP-1/glucagon receptor agonist

InvestigationalNot compoundable

Investigational. FDA explicitly states retatrutide cannot be used in compounding under federal law. Enforcement pressure sharpened in mid-2026: FDA's Import Alert 66-80, republished August 13, 2026, includes import entries keyed to the word 'Retatrutide'; the UK MHRA said on July 24, 2026 that anyone selling retatrutide in the UK is doing so illegally; and on August 12, 2026 Eli Lilly filed six lawsuits against research-use-only sellers, a compounding pharmacy, and a med spa, arguing the 'research use only' label is pretext for selling an unapproved new drug. Those complaints are allegations — no defendant has been found liable.

No ruling, injunction, or settlement in the Lilly cases as of August 22, 2026.

Cagrilintide

Amylin analog

InvestigationalNot compoundable

Investigational. FDA explicitly states cagrilintide cannot be used in compounding under federal law.

Not compoundable

No current federal bulk-substance path is identified for routine compounding, or FDA has explicitly stated the substance cannot be used in compounding.

18 tracked
Kisspeptin-10

Kisspeptin fragment

Category 2InvestigationalNot compoundable

Category 2 under 503A, added September 29, 2023, and still there. After FDA's April 2026 restructure, kisspeptin-10, ipamorelin acetate, GHRP-2 (injectable/nasal routes), and GHRP-6 are the four peptides left in the active category 2 table — everything else moved to the 'nominated but withdrawn' table. Treat as not currently compoundable.

Ipamorelin acetate

Growth hormone secretagogue

Category 2PCAC reviewNot compoundable

Category 2 for 503B outsourcing facilities, added September 29, 2023, and still there — one of four peptides remaining in FDA's active category 2 table. Its separate 503A nomination was withdrawn, so ipamorelin acetate is the one substance that appears in both of FDA's tables at once. Not a Category 1 503A bulk substance.

GHRP-2

Growth hormone releasing peptide-2

Category 2Not compoundable

Category 2 for injectable and nasal routes in FDA's safety-risk materials. Treat as not currently compoundable.

GHRP-6

Growth hormone releasing peptide-6

Category 2Not compoundable

Category 2 in FDA's safety-risk materials. Treat as not currently compoundable.

Ibutamoren

MK-677

Category 2Not compoundableNon-peptide secretagogue

Category 2 in the current FDA 503A list. Included because it is frequently grouped with growth hormone peptides in consumer searches.

BPC-157

BPC-157 free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend BPC-157, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported. FDA's own review team had recommended against all seven substances on the agenda, and its slides state that BPC-157 acetate 'is not well-characterized.' A recommendation is advisory. FDA has taken no action, so BPC-157 is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

KPV

KPV free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend KPV, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated use was wound healing and inflammatory conditions. A recommendation is advisory. FDA has taken no action, so KPV is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

TB-500

TB-500 free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend TB-500, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated use was wound healing. FDA opened the meeting with a talk on 'conflated bulks': one trade name can map to different sequences from different suppliers, which is exactly the TB-500 problem — the name is used for both full-length thymosin beta-4 and a short fragment. A recommendation is advisory. FDA has taken no action, so TB-500 is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

MOTS-c

MOTS-c free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend MOTS-c, free base and acetate salt, for the list — 7 yes, 5 no, 2 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated uses were obesity and osteoporosis. A recommendation is advisory. FDA has taken no action, so MOTS-c is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

Semax

Semax free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 24, 2026 the FDA advisory committee voted to recommend Semax, free base and acetate salt, for the list — 8 yes, 5 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated uses were cerebral ischemia, migraine, and trigeminal neuralgia. A recommendation is advisory. FDA has taken no action, so Semax is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

Emideltide / DSIP

Delta sleep-inducing peptide

PCAC hub
PCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. Emideltide was the only one of the seven substances the advisory committee voted against on July 24, 2026 — 6 yes, 7 no, 1 abstain as reported. FDA's evaluated uses were opioid withdrawal, chronic insomnia, and narcolepsy. Both the FDA review team and the committee landed against inclusion, so there is no pathway in progress.

No FDA action expected from this vote. Treat as not compoundable.

Epitalon

Epitalon free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 24, 2026 the FDA advisory committee voted to recommend Epitalon, free base and acetate salt, for the list — 7 yes, 4 no, 1 abstain as reported (some outlets reported 7-5-1; only 12 members were eligible to vote on this substance). FDA's evaluated use was insomnia. A recommendation is advisory. FDA has taken no action, so Epitalon is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

AOD-9604

hGH fragment 176-191

PCAC reviewNot compoundable

Not currently Category 1. FDA PCAC reviewed AOD-9604-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable.

CJC-1295

CJC-1295 related bulk drug substances

PCAC reviewNot compoundable

Not currently Category 1. FDA PCAC reviewed CJC-1295-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable.

Thymosin alpha-1

Thymosin alpha-1 free base and acetate

PCAC reviewNot compoundable

Not currently Category 1. FDA PCAC reviewed thymosin alpha-1-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable.

Selank

Selank acetate / TP-7

Not compoundable

Not currently Category 1. Selank acetate (TP-7) sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish a safety-risk finding for it. It is not on the 503A Bulks List, was not on the July 2026 PCAC agenda, and is not compoundable.

Retatrutide

Triple GIP/GLP-1/glucagon receptor agonist

InvestigationalNot compoundable

Investigational. FDA explicitly states retatrutide cannot be used in compounding under federal law. Enforcement pressure sharpened in mid-2026: FDA's Import Alert 66-80, republished August 13, 2026, includes import entries keyed to the word 'Retatrutide'; the UK MHRA said on July 24, 2026 that anyone selling retatrutide in the UK is doing so illegally; and on August 12, 2026 Eli Lilly filed six lawsuits against research-use-only sellers, a compounding pharmacy, and a med spa, arguing the 'research use only' label is pretext for selling an unapproved new drug. Those complaints are allegations — no defendant has been found liable.

No ruling, injunction, or settlement in the Lilly cases as of August 22, 2026.

Cagrilintide

Amylin analog

InvestigationalNot compoundable

Investigational. FDA explicitly states cagrilintide cannot be used in compounding under federal law.

Full tracker

Deduplicated peptide-by-peptide table

The list focuses on Peptide Garden profiles and high-interest FDA compounding substances. It is not a complete reproduction of every FDA bulk drug substance table.

PeptideStatusPractical postureSource basis
Semaglutide

GLP-1 receptor agonist

FDA-approved

FDA-approved products exist. Broad copy compounding is not a Category 1 peptide-bulk pathway, and FDA flags unapproved GLP-1 products and salt forms as safety risks. FDA's May 1, 2026 proposal to exclude semaglutide from the 503B outsourcing-facility bulks list on a 'no clinical need' finding closed for comment on or about July 30, 2026. As of August 22, 2026 FDA had issued no final determination and no follow-on Federal Register document, and no court challenge to the proposal had been filed. Separately, on July 28, 2026 FDA published revised draft product-specific guidances for generic semaglutide — a bioequivalence-recommendation update, not an approval, and not a change to compounding law.

Comment period on the proposed 503B bulks-list exclusion closed July 30, 2026 (docket FDA-2018-N-3240). Watching for a final FDA determination; none had issued as of August 22, 2026.

FDA-approved products, FDA GLP-1 compounding safety communications, the May 2026 proposed 503B bulks-list exclusion with a Federal Register check through August 22, 2026, and FDA's July 2026 revised draft generic-peptide guidances.

Tirzepatide

Dual GIP/GLP-1 receptor agonist

FDA-approved

FDA-approved products exist. Copy compounding is constrained by approved-drug and shortage rules, not Category 1 peptide-bulk status. FDA's May 1, 2026 proposal to exclude tirzepatide from the 503B outsourcing-facility bulks list on a 'no clinical need' finding closed for comment on or about July 30, 2026. As of August 22, 2026 FDA had issued no final determination and no follow-on Federal Register document. Separately, on July 28, 2026 FDA published revised draft product-specific guidances for generic tirzepatide — a bioequivalence-recommendation update, not an approval, and not a change to compounding law.

Comment period on the proposed 503B bulks-list exclusion closed July 30, 2026 (docket FDA-2018-N-3240). Watching for a final FDA determination; none had issued as of August 22, 2026.

FDA-approved products, FDA GLP-1 compounding safety communications, the May 2026 proposed 503B bulks-list exclusion with a Federal Register check through August 22, 2026, and FDA's July 2026 revised draft generic-peptide guidances.

Liraglutide

GLP-1 receptor agonist

FDA-approved

FDA-approved products exist. This is an approved-drug pathway, not a Category 1 peptide-bulk listing. FDA's May 1, 2026 proposal to exclude liraglutide from the 503B outsourcing-facility bulks list on a 'no clinical need' finding closed for comment on or about July 30, 2026, and FDA had issued no final determination as of August 22, 2026. Liraglutide is also covered by FDA's July 28, 2026 revised draft product-specific guidances for generic peptide products.

Comment period on the proposed 503B bulks-list exclusion closed July 30, 2026 (docket FDA-2018-N-3240). Watching for a final FDA determination; none had issued as of August 22, 2026.

FDA-approved product records, the May 2026 proposed 503B bulks-list exclusion with a Federal Register check through August 22, 2026, and FDA's July 2026 revised draft generic-peptide guidances.

Tesamorelin

GHRH analog

FDA-approved

FDA-approved product exists. Any compounding analysis starts from approved-drug rules rather than Category 1 bulk status.

FDA-approved product records.

PT-141 / Bremelanotide

Melanocortin receptor agonist

FDA-approved

FDA-approved product exists for a specific indication. That approval does not validate non-approved indications.

FDA-approved product records.

Oxytocin

Neuropeptide hormone

FDA-approved

FDA-approved drug products exist. This is not a consumer peptide-bulk compounding status.

FDA-approved product records.

Elamipretide

Mitochondria-targeted peptide

FDA-approved

FDA-approved product exists under an approved-drug pathway. It is not a Category 1 compounded bulk peptide.

FDA-approved product records.

GHK-Cu

Glycyl-L-histidyl-L-lysine copper

Category 1PCAC review

Category 1 in FDA's 503A materials for non-injectable routes. Injectable GHK-Cu is not on that footing and is not authorized for compounding. Its position moved in April 2026: injectable GHK-Cu was one of the twelve peptides shifted off FDA's active category 2 table into the new 'nominated but withdrawn' table. FDA still publishes its safety-risk finding, and the substance is no closer to being compoundable — a withdrawn nomination is a nomination that will not be decided, not a clearance. Law-firm reporting from the July 2026 PCAC meeting says FDA signalled a further PCAC consultation on GHK-Cu and four other peptides; FDA has published no meeting notice, docket, or date for it, so we treat the timing as unconfirmed.

A second peptide PCAC meeting including GHK-Cu is reported but unscheduled. Watching the FDA advisory committee calendar and the Federal Register.

FDA 503A bulk-substance pages and safety-risk page, checked August 22, 2026. The follow-on PCAC consultation is secondary reporting only — no FDA primary source exists yet.

NAD+

Nicotinamide adenine dinucleotide

Category 1Not a peptide

Category 1 in the current FDA 503A list. It is a coenzyme, not a peptide, and Category 1 is not FDA drug approval.

Current FDA 503A category PDF.

Vasoactive intestinal peptide

VIP

Category 1

Category 1 in the current FDA 503A list if all compounding conditions are met.

Current FDA 503A category PDF.

Sermorelin

GHRH (1-29)

Other compoundable path

Not shown as a May 2026 Category 1 peptide-bulk entry. Peptide Garden tracks it separately because its profile cites a prior FDA approval, withdrawal not for safety or effectiveness, and an established compounding pathway.

Secondary Peptide Garden profile context; not counted as a Category 1 tracker entry.

Kisspeptin-10

Kisspeptin fragment

Category 2InvestigationalNot compoundable

Category 2 under 503A, added September 29, 2023, and still there. After FDA's April 2026 restructure, kisspeptin-10, ipamorelin acetate, GHRP-2 (injectable/nasal routes), and GHRP-6 are the four peptides left in the active category 2 table — everything else moved to the 'nominated but withdrawn' table. Treat as not currently compoundable.

FDA's category 2 table, re-read line by line on August 22, 2026, plus profile clinical-trial context.

Ipamorelin acetate

Growth hormone secretagogue

Category 2PCAC reviewNot compoundable

Category 2 for 503B outsourcing facilities, added September 29, 2023, and still there — one of four peptides remaining in FDA's active category 2 table. Its separate 503A nomination was withdrawn, so ipamorelin acetate is the one substance that appears in both of FDA's tables at once. Not a Category 1 503A bulk substance.

FDA safety-risk page, re-read line by line on August 22, 2026, and prior PCAC review context; no current Category 1 listing identified.

GHRP-2

Growth hormone releasing peptide-2

Category 2Not compoundable

Category 2 for injectable and nasal routes in FDA's safety-risk materials. Treat as not currently compoundable.

FDA safety-risk page.

GHRP-6

Growth hormone releasing peptide-6

Category 2Not compoundable

Category 2 in FDA's safety-risk materials. Treat as not currently compoundable.

FDA safety-risk page.

Ibutamoren

MK-677

Category 2Not compoundableNon-peptide secretagogue

Category 2 in the current FDA 503A list. Included because it is frequently grouped with growth hormone peptides in consumer searches.

Current FDA 503A category PDF.

BPC-157

BPC-157 free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend BPC-157, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported. FDA's own review team had recommended against all seven substances on the agenda, and its slides state that BPC-157 acetate 'is not well-characterized.' A recommendation is advisory. FDA has taken no action, so BPC-157 is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. Tallies are as reported by legal and trade press; FDA published no official tallies, minutes, or transcript.

KPV

KPV free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend KPV, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated use was wound healing and inflammatory conditions. A recommendation is advisory. FDA has taken no action, so KPV is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. Tallies are as reported; FDA published no official tallies, minutes, or transcript.

TB-500

TB-500 free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend TB-500, free base and acetate salt, for the list — 8 yes, 6 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated use was wound healing. FDA opened the meeting with a talk on 'conflated bulks': one trade name can map to different sequences from different suppliers, which is exactly the TB-500 problem — the name is used for both full-length thymosin beta-4 and a short fragment. A recommendation is advisory. FDA has taken no action, so TB-500 is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. FDA's agenda names the substance simply as 'TB-500 (free base) / TB-500 acetate.' Tallies are as reported; FDA published no official tallies, minutes, or transcript.

MOTS-c

MOTS-c free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 23, 2026 the FDA advisory committee voted to recommend MOTS-c, free base and acetate salt, for the list — 7 yes, 5 no, 2 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated uses were obesity and osteoporosis. A recommendation is advisory. FDA has taken no action, so MOTS-c is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. Tallies are as reported; FDA published no official tallies, minutes, or transcript.

Semax

Semax free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 24, 2026 the FDA advisory committee voted to recommend Semax, free base and acetate salt, for the list — 8 yes, 5 no, 1 abstain as reported, against FDA's own review team's recommendation to exclude it. FDA's evaluated uses were cerebral ischemia, migraine, and trigeminal neuralgia. A recommendation is advisory. FDA has taken no action, so Semax is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. Tallies are as reported; FDA published no official tallies, minutes, or transcript.

Emideltide / DSIP

Delta sleep-inducing peptide

PCAC hub
PCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. Emideltide was the only one of the seven substances the advisory committee voted against on July 24, 2026 — 6 yes, 7 no, 1 abstain as reported. FDA's evaluated uses were opioid withdrawal, chronic insomnia, and narcolepsy. Both the FDA review team and the committee landed against inclusion, so there is no pathway in progress.

No FDA action expected from this vote. Treat as not compoundable.

FDA's July 2026 PCAC meeting page, voting questions, and presentation slides, plus a Federal Register check on August 22, 2026. Tallies are as reported; FDA published no official tallies, minutes, or transcript.

Epitalon

Epitalon free base and acetate salt

PCAC hub
PCAC recommendedPCAC reviewNot compoundable

Not on the 503A Bulks List and not Category 1. On July 24, 2026 the FDA advisory committee voted to recommend Epitalon, free base and acetate salt, for the list — 7 yes, 4 no, 1 abstain as reported (some outlets reported 7-5-1; only 12 members were eligible to vote on this substance). FDA's evaluated use was insomnia. A recommendation is advisory. FDA has taken no action, so Epitalon is not legal to compound today.

FDA must publish a proposed rule and run notice-and-comment before anything changes. None had issued as of August 22, 2026.

FDA's July 2026 PCAC meeting page, voting questions, final meeting roster, and presentation slides, plus a Federal Register check on August 22, 2026 showing no proposed rule or list change. Tallies are as reported; FDA published no official tallies, minutes, or transcript.

AOD-9604

hGH fragment 176-191

PCAC reviewNot compoundable

Not currently Category 1. FDA PCAC reviewed AOD-9604-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable.

FDA December 2024 PCAC notice, and FDA's safety-risk page re-read on August 22, 2026.

CJC-1295

CJC-1295 related bulk drug substances

PCAC reviewNot compoundable

Not currently Category 1. FDA PCAC reviewed CJC-1295-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable.

FDA December 2024 PCAC notice, and FDA's safety-risk page re-read on August 22, 2026.

Thymosin alpha-1

Thymosin alpha-1 free base and acetate

PCAC reviewNot compoundable

Not currently Category 1. FDA PCAC reviewed thymosin alpha-1-related bulk substances in December 2024; no current Category 1 listing identified. The substance sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish its safety-risk finding. Not compoundable.

FDA December 2024 PCAC notice, and FDA's safety-risk page re-read on August 22, 2026.

Selank

Selank acetate / TP-7

Not compoundable

Not currently Category 1. Selank acetate (TP-7) sits in FDA's 'nominated but withdrawn' table, where FDA continues to publish a safety-risk finding for it. It is not on the 503A Bulks List, was not on the July 2026 PCAC agenda, and is not compoundable.

FDA's safety-risk page, re-read line by line on August 22, 2026, and the current 503A category page.

Retatrutide

Triple GIP/GLP-1/glucagon receptor agonist

InvestigationalNot compoundable

Investigational. FDA explicitly states retatrutide cannot be used in compounding under federal law. Enforcement pressure sharpened in mid-2026: FDA's Import Alert 66-80, republished August 13, 2026, includes import entries keyed to the word 'Retatrutide'; the UK MHRA said on July 24, 2026 that anyone selling retatrutide in the UK is doing so illegally; and on August 12, 2026 Eli Lilly filed six lawsuits against research-use-only sellers, a compounding pharmacy, and a med spa, arguing the 'research use only' label is pretext for selling an unapproved new drug. Those complaints are allegations — no defendant has been found liable.

No ruling, injunction, or settlement in the Lilly cases as of August 22, 2026.

FDA GLP-1 compounding safety page, FDA Import Alert 66-80, and the August 12, 2026 Eli Lilly filings and public statement.

Cagrilintide

Amylin analog

InvestigationalNot compoundable

Investigational. FDA explicitly states cagrilintide cannot be used in compounding under federal law.

FDA GLP-1 compounding safety page.

Source monitor

Official sources checked for this page

Regulatory pages can change without much notice. These are the specific source surfaces this tracker currently uses.

Checked August 22, 2026

FDA 503A bulk drug substances page

FDA's page defining the 503A Bulks List and the interim-policy categories used for nominated bulk drug substances. Its FDA-stamped 'content current as of' date was May 14, 2026 when re-checked on August 22, 2026. No peptide has been added to the statutory 503A Bulks List. The April 2026 category-2 restructure happened on FDA's separate safety-risk page, not this one.

Open source

Checked August 22, 2026

FDA safety-risk bulk drug substances page

FDA's safety-risk page for nominated bulk drug substances. FDA-stamped current as of April 22, 2026, unchanged when re-checked on August 22, 2026. On that April date FDA restructured the page into two tables: an active 'under category 2 of the interim policies' table, now 14 substances, and a new 'nominated but withdrawn' table, now 17. Twelve peptides moved from the first table to the second — BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), epitalon, injectable GHK-Cu, KPV, Melanotan II, PEG-MGF, MOTS-c, semax, and TB-500. FDA still publishes a safety-risk finding for every one of them. Withdrawal of a nomination does not make a substance compoundable.

Open source

Checked August 22, 2026

FDA July 23-24, 2026 PCAC meeting page

Official FDA meeting page for the July 2026 peptide bulk-substance agenda, including each substance's FDA-evaluated use and the posted event materials. As of August 22, 2026 FDA had not updated the page with an outcome and had published no summary minutes or transcript.

Open source

Checked August 22, 2026

FDA PCAC July 2026 voting questions

The official FDA voting-questions document for the meeting. It shows 14 separate votes — free base and acetate salt were voted on separately for each of the seven substances. FDA did not publish the resulting tallies.

Open source

Checked August 22, 2026

FDA PCAC July 23, 2026 presentation slides

FDA's own slide deck. FDA's multidisciplinary review team proposed that none of the seven substances be included on the 503A Bulks List, citing characterization gaps, peptide-related and synthesis-process impurities, and immunogenicity/aggregation risk. The meeting opened with an FDA talk on 'conflated bulks' — one trade name mapping to different sequences from different suppliers.

Open source

Checked August 22, 2026

Federal Register PCAC meeting notice (FR 2026-07361)

The April 16, 2026 Federal Register notice establishing the July 2026 PCAC meeting and its public docket, FDA-2025-N-6895 (closed July 22, 2026). As of August 22, 2026 this remains the most recent Federal Register action relating to the 503A Bulks List and these peptides — no proposed rule has followed the vote.

Open source

Checked May 16, 2026

FDA December 4, 2024 PCAC meeting notice

Official FDA advisory committee notice for AOD-9604, CJC-1295, and thymosin alpha-1 related bulk-substance review.

Open source

Checked May 16, 2026

FDA GLP-1 compounding safety page

FDA safety page for unapproved GLP-1 drugs, including explicit statements about semaglutide, tirzepatide, retatrutide, and cagrilintide compounding.

Open source

Checked August 22, 2026

FDA proposed 503B bulks-list exclusion for GLP-1s

FDA Federal Register notice (published May 1, 2026; FR doc 2026-08552) proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list on a finding of no clinical need. The comment period was extended 30 days and closed on or about July 30, 2026 (FR Doc 2026-12937; docket FDA-2018-N-3240). A Federal Register sweep on August 22, 2026 found no final determination, no withdrawal, and no re-opening. The proposal remains a proposal. This is a 503B action, not a 503A category change, and does not alter the drugs' FDA-approved status.

Open source

Checked August 22, 2026

FDA revised draft product-specific guidances for generic peptides

On July 28, 2026 FDA published 17 revised draft product-specific guidances for generic peptide products — covering semaglutide, tirzepatide, liraglutide, teriparatide, glucagon, pegcetacoplan, and vosoritide among others — and withdrew its May 2021 guidance on ANDAs for highly purified synthetic peptides referencing rDNA-origin listed drugs. These are draft bioequivalence recommendations open for comment, not approvals of any generic product, and they do not change compounding law.

Open source

Checked August 22, 2026

FDA Import Alert 66-80 (GLP-1 bulk drug substances)

FDA's detention-without-physical-examination alert for imported GLP-1 receptor agonist bulk drug substances, republished August 13, 2026. It authorizes detention of foreign-sourced GLP-1 APIs except for green-listed firm/product pairs, and its product-code scope reaches peptide APIs for prescription compounding and entries keyed to the word 'Retatrutide.'

Open source

Checked August 22, 2026

Eli Lilly retatrutide enforcement announcement

On August 12, 2026 Eli Lilly filed six lawsuits over retatrutide against research-use-only peptide sellers, a compounding pharmacy, and a med spa, and publicly asked marketplaces and payment processors to de-platform sellers. The complaints plead state consumer-protection claims predicated on state analogues of the federal ban on unapproved new drugs. These are newly filed allegations; no defendant has been found liable.

Open source

Checked May 16, 2026

FDA compounding questions and answers

FDA plain-language compounding FAQ explaining that compounded drugs are not FDA-approved.

Open source

Checked May 16, 2026

Drugs@FDA approved drug records

FDA database for approved drug products, labels, approval letters, and regulatory history.

Open source

Disclaimer

This tracker is educational and reflects source checks performed on October 1, 2026. It is not legal advice, medical advice, prescribing guidance, or a sourcing recommendation. Consult qualified counsel or a licensed healthcare professional for decisions that depend on current law or patient-specific care.